Biosimilars and market access: a question of comparability and costs?
about
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?The economic burden of fragile x syndrome: healthcare resource utilization in the United States.Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelEpoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.Biosimilars: part 2: potential concerns and challenges for p&t committees.Barriers to the uptake of biosimilars and possible solutions: a Belgian case study.Windows of opportunities and technological innovation in the Brazilian pharmaceutical industry.Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.Biosimilars: part 1: proposed regulatory criteria for FDA approval.Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
P2860
Q26863707-77CE69DA-5FFC-4B09-9AD1-1B7A56B016F6Q33652798-FBBF564A-3844-490C-8E1A-6B04DDBFFD9DQ33740641-8875FF86-5030-4D85-AFBC-25EB0EF41CDBQ35162053-5DFF7DB9-AB76-4E14-A2EA-D314947DA8F5Q36164727-F9765316-7364-49E9-962B-E36D3BF2BAE6Q37081551-5B548F5E-FBD0-4D4F-A3CF-7460A87BA7D2Q38209872-58FB52EC-693E-4169-957C-2015DF1D3D58Q39201672-8FA6B2C4-4A14-4FB0-802C-2182B05FD005Q40567012-28F02C1C-7804-4914-B317-80EB6E466B40Q42545996-14FEF760-3CE0-45D9-97DB-73C1E110E0E9Q47656264-D38FBCFA-46F0-41AF-B8F6-0EF00517EB5E
P2860
Biosimilars and market access: a question of comparability and costs?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biosimilars and market access: a question of comparability and costs?
@en
Biosimilars and market access: a question of comparability and costs?
@nl
type
label
Biosimilars and market access: a question of comparability and costs?
@en
Biosimilars and market access: a question of comparability and costs?
@nl
prefLabel
Biosimilars and market access: a question of comparability and costs?
@en
Biosimilars and market access: a question of comparability and costs?
@nl
P2860
P1433
P1476
Biosimilars and market access: a question of comparability and costs?
@en
P2093
Gilbert Verbeken
Steven Simoens
P2860
P2888
P304
P356
10.1007/S11523-011-0192-7
P577
2012-01-17T00:00:00Z